CN106317195B - Ring histidyl--KGRPAK, synthesis, thrombus related activity and application - Google Patents
Ring histidyl--KGRPAK, synthesis, thrombus related activity and application Download PDFInfo
- Publication number
- CN106317195B CN106317195B CN201510352820.1A CN201510352820A CN106317195B CN 106317195 B CN106317195 B CN 106317195B CN 201510352820 A CN201510352820 A CN 201510352820A CN 106317195 B CN106317195 B CN 106317195B
- Authority
- CN
- China
- Prior art keywords
- lys
- boc
- pro
- ala
- obzl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses following formula ring histidyl--KGRPAK ((6s) -4,5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -6- formyl-Lys-Gly-Arg-Pro-Ala-Lys), its preparation method and its synthesis are disclosed, the effect that it treats rats with stroke is disclosed, thus the invention discloses it to prepare the application in ishemic stroke drug.
Description
Technical field
The present invention relates to (6s) -4 of following formula, 5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -6- formyl-Lys-
Gly-Arg-Pro-Ala-Lys is related to its preparation method, is related to the effect that it treats ishemic stroke, thus the present invention relates to
And it is preparing the application in ishemic stroke drug.The invention belongs to biomedicine fields.
Background technique
Ishemic stroke be it is a kind of more typically and the serious cranial vascular disease of harm, feature be disease incidence is high, case fatality rate is high,
Disability rate height and high recurrence rate.Clinical treatment ishemic stroke faces the reality of not active drug, especially apoplexy face 4h at present
Above patient is non-extremely i.e. residual.Invention is clinical important need to the effective drug of patient of apoplexy face 4h or more.Inventor
The imidazolinium compounds of Formula II was once disclosed on the ischemia/reperfusion in rats apoplexy model for 24 hours of apoplexy face, shows outstanding curative effect.Connect
The imidazolinium compounds of 6 days Formula II of continuous intravenous injection, 1 time a day, initial dose are 5 μm of ol/kg, and rear 5 dosage is 2 μ
Mol/kg has outstanding curative effect.Aa in formula1And aa2It can be to exist simultaneously, aa1In the presence of but aa2It is not present, or is not present simultaneously；When
aa1And aa2When existing simultaneously, aa1For R (Arg), and aa2For G (Gly), A (Ala) or Q (Gln)；Work as aa1In the presence of but aa2It does not deposit
When, aa1For R (Arg)；aa3It can be S (Ser), V (Val) or F (Phe).Since the substituted imidazoline structural unit of Formula II compares
Complexity needs to simplify.
Inventor is passing through 3 years experimental studies, 4,5,6,7- tetrahydro -3H- imidazoles [4,5-c] of discovery and pyridine -6- first
Acyl group replaces the substituted imidazoline structural unit of Formula II that can obtain, and structure is simple and the unexpected double technique effect of good effect
Fruit.According to this discovery, the present invention is inventors herein proposed.
Summary of the invention
First content of the invention is to provide (6s) -4 of following formula, 5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -
6- formyl-Lys-Gly-Arg-Pro-Ala-Lys.
Second content of the invention is to provide (6s) -4 of above formula, 5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -
The synthetic method of 6- formyl-Lys-Gly-Arg-Pro-Ala-Lys, this method comprises:
(1) in the presence of dicyclohexylcarbodiimide (DCC) Boc-Pro in anhydrous THF with and N- hydroxysuccinimidyl acyl Asia
Amine (HOSu) condensation is Boc-Pro-OSu, in NaHCO3In the presence of Boc-Pro-OSu reacted with Ala generate Boc-Pro-Ala；
(2) Boc-Pro-Ala is Boc-Pro- with Lys (Z)-OBzl condensation in anhydrous THF in the presence of DCC and HOBt
Ala-Lys(Z)-OBzl；
(3) Boc-Pro-Ala-Lys (Z)-OBzl sloughs the generation of Boc protecting group in hydrogen chloride-ethyl acetate solution
Pro-Ala-Lys(Z)-OBzl；
(4) Boc-Arg (NO in the presence of DCC and HOBt2) be condensed in anhydrous THF with Pro-Ala-Lys (Z)-OBzl
For Boc-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl；
(5) Boc-Arg (NO in hydrogen chloride-ethyl acetate solution2)-Pro-Ala-Lys (Z)-OBzl slough Boc protection
Base generates Arg (NO2)-Pro-Ala-Lys(Z)-OBzl；
(6) in the presence of DCC and HOBt Boc-Gly in anhydrous THF with Arg (NO2)-Pro-Ala-Lys(Z)-OBzl
Condensation is Boc-Gly-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl；
(7) Boc-Gly-Arg (NO in hydrogen chloride-ethyl acetate solution2)-Pro-Ala-Lys (Z)-OBzl sloughs Boc
Protecting group generates Gly-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl；
(8) in the presence of dilute sulfuric acid, formaldehyde reacts at 60 DEG C with L-Histidine, generates (6s) -4,5,6,7- tetrahydros -
3H- imidazoles [4,5-c] and pyridine -6- carboxylic acid；
(9) bis--Boc-4 of (6s) -3,5- in the presence of DCC and HOBt, 5,6,7- tetrahydro -3H- imidazo [4,5-c] pyrroles
Pyridine -6- carboxylic acid is bis--Boc-4 of (6s) -3,5-, 5,6,7- tetrahydros-with Lys (Boc)-OBzl condensation in anhydrous tetrahydro furan
3H- imidazo [4,5-c] pyridine -6- formyl-L-Lys (Boc)-OBzl.
(10) bis--Boc-4 of (6s) -3,5- in the presence of Pd/C, 5,6,7- tetrahydro -3H- imidazo [4,5-c] pyridine -6-
Formyl-L-Lys (Boc)-OBzl sloughs OBzl in methanol solution and generates bis--Boc-4 of (6s) -3,5-, 5,6,7- tetrahydro -3H-
Imidazo [4,5-c] pyridine -6- formyl-L-Lys (Boc)；
(11) bis--Boc-4 of (6s) -3,5- in the presence of DCC and HOBt, 5,6,7- tetrahydro -3H- imidazo [4,5-c] pyrroles
Pyridine -6- formyl-L-Lys (Boc) in anhydrous tetrahydro furan with HClGly-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl
Condensation is bis--Boc-4 of (6s) -3,5-, 5,6,7- tetrahydro -3H- imidazo [4,5-c] pyridine -6- formyl-L-Lys (Boc) -
Gly-Arg(NO2)-Pro-Ala-Lys(Z)-OBzl。
(12) compound prepared by step (11) is sloughed into protecting group, obtains above formula compound represented.
Wherein the HOBt is the breviary term of N- hydroxy benzo triazole, and DCC is the breviary of dicyclohexyl carbonyl diimine
Term, Boc are the breviary term of tertbutyloxycarbonyl, and Pd/C is palladium/carbon.
Third content of the invention is evaluation above formula (6s) -4,5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -
The activity of 6- formyl-Lys-Gly-Arg-Pro-Ala-Lys treatment ishemic stroke.
Detailed description of the invention
Fig. 1 (6s) -4,5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -6- formyl-Lys-Gly-Arg-Pro-Ala-
Synthetic route (i) H of Lys2SO4, HCHO, 60 DEG C；(ii) 1N NaOH, (Boc)2O；(iii) DCC, HOBt, NMM；(iv)H2,
Pd/C；(v) 4N hydrogen chloride-ethyl acetate solution；(vi)TFA/TFSA；(vii) HOSu, DCC.
Specific embodiment
In order to which the present invention is further explained, a series of embodiments are given below.These embodiments be entirely it is illustrative, it
Only be used to the present invention is specifically described, be not construed as limitation of the present invention.
Embodiment 1 prepares (6s) -4,5,6,7- tetrahydro -3H- imidazo [4,5-c] pyridine -6- carboxylic acids (1)
10g (64.5mmol) L-His 80mL distilled water and 20mL formaldehyde mixed solution are dissolved, are then added dropwise inward
The dense H of 1mL2SO4, 60 DEG C microwave reaction 5 hours, be cooled to room temperature, under ice bath in compound of reaction be added dropwise concentrated ammonia liquor tune pH to 7,
There are a large amount of Precipitations.Filtering, obtains 10.5g (97%) title compound, is colorless solid.ESI-MS(m/z)167[M+H]+。
Embodiment 2 prepares bis--Boc-4 of (6s) -3,5-, 5,6,7- tetrahydro -3H- imidazo [4,5-c] pyridine -6- carboxylic acids
(2)
By 1.67g (10mmol) (6s) -4 under ice bath, 5,6,7- tetrahydro -3H- imidazo [4,5-c] pyridine -6- carboxylic acids are molten
In 5ml2N sodium hydrate aqueous solution.Add 5.23g (24mmol) (Boc) into the reaction solution2The solution of O and 10mL dioxane.
It is stirred at room temperature, TLC (CH2Cl2: MeOH=15: 1) monitors reaction raw material point and disappear.After the reaction was completed, it filters, filtrate decompression concentration
Remove dioxane.Remaining water layer saturation KHSO4Aqueous solution is acidified to pH value to 2, is extracted with ethyl acetate three times, merges
Ethyl acetate layer, and with a small amount of water backwash, ethyl acetate layer anhydrous Na2SO4It dries, filters, what is be concentrated under reduced pressure to give is faint yellow
The immersion of solid ethyl acetate is worn away, and is filtered, is obtained 1.55g (42%) title compound, is colorless solid.ESI-MS(m/z)367
[M+H]+。
Embodiment 3 prepares bis--Boc-4 of (6s) -3,5-, 5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -6- formyl -
Lys(Boc)-OBzl(3)
Ice bath and stirring are lower 3.67g (10.0mmol) (6s) -3, bis--Boc-4 of 5-, 5,6,7- tetrahydro -3H- imidazos [4,
5-c] pyridine -6- carboxylic acid, 1.48g (11.0mmol) HOBt and 2.47g (12.0mmol) DCC adds 50ml anhydrous THF dissolution, reaction
Liquid activates 30 minutes.Then by 3.91g (10.5mmol) TosLys (Boc)-OBzl and the anhydrous THF of 50mL and 1.0mL is used
In the reaction solution that the hanging drop that NMM adjusts pH to 9 is added to activation.Ice bath is removed, is stirred at room temperature 12 hours, filters out dicyclohexyl
Urea (DCU).Filtrate decompression is concentrated to dryness, residue with Ethyl acetate dissolution, then filters out DCU.Filtrate layers are successively with saturation
NaHCO3Solution is washed 3 times, and saturation NaCl solution is washed 3 times, is saturated KHSO4Solution is washed 3 times, and saturation NaCl solution is washed 3 times, is saturated
NaHCO3Solution is washed 3 times, and saturation NaCl solution is washed 3 times, ethyl acetate layer anhydrous Na2SO4Dry, filter, filtrate decompression it is dense
Contracting, residue purify to obtain 3.97g (58%) title compound through column chromatography (petroleum ether/acetone system 8: 1-2: 1), are colourless solid
Body, ESI-MS (m/z) 686 [M+H]+。
Embodiment 4 prepares bis--Boc-4 of (6s) -3,5-, 5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -6- formyl -
L-Lys(Boc)(4)
Weigh 200mg (0.29mmol) (6s) -3,5-, bis--Boc-4,5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -
6- formyl-L-Lys (Boc)-OBzl after the dissolution of 10mL methanol, is added 20mg Pd/C, first uses vacuum in 50mL eggplant-shape bottle
Water pump takes the air in reaction flask away, then passes to hydrogen, repeatedly three times, finally keeps logical hydrogen state response 12 small
When, using TLC (petroleum ether: acetone=3: 1) monitoring to raw material spot disappear after, be filtered under diminished pressure, concentrate filtrate to dry
160mg (92%) title compound, be colorless solid, ESI/MS (m/e): 596 [M+H]+。
Embodiment 5 prepares HClPro-Ala-Lys (Z)-OBzl
5-1) prepare Boc-Pro-Ala
Add 0.637g (5mmol) N- under ice bath into the solution of the anhydrous THF of 1.075g (5.0mmol) Boc-Pro and 20mL
HOSu NHS (HOSu), and make to be completely dissolved.Add a small amount of anhydrous THF and 1.236g (6.0 mmol) two into the solution
The solution of cyclohexyl carbonyl diimine (DCC).It is stirred at room temperature 7 hours, TLC (methylene chloride: methanol=10: 1) monitors Boc-Pro and disappears
It loses.DCU is filtered out, filtrate decompression concentration removes THF.Residue is first dissolved with ethyl acetate, then successively with saturation NaHCO3Water
Molten and saturation NaCl aqueous solution is washed.Ethyl acetate layer is concentrated to dryness, and appropriate THF dissolution is added in residue.Into the solution
Add 0.489g (5.5mmol) the Ala solution for having been dissolved in a small amount of water.Obtained reaction solution NaHCO3Solid tune pH to 9, room temperature is anti-
It answers 12 hours, is concentrated under reduced pressure and removes THF, residue adds 5mL water to dissolve, with saturation KHSO4Aqueous solution tune pH to 2, with acetic acid second
Ester repeatedly extracts on a small quantity, and combined ethyl acetate layer is washed till neutrality with saturation NaCl aqueous solution, dry with anhydrous sodium sulfate.It crosses
Filter, filtrate decompression are concentrated to give 1.41g (98%) title compound, are colorless solid.ESI-MS (m/e): 285 [M-H]-。
5-2) prepare Boc-Pro-Ala-Lys (Z)-OBzl
Using the method for embodiment 3 from 1.43g (5.0mmol) Boc-Pro-Ala and 2.71g (5.0mmol) Lys (Z)-
OBzl obtains 3.09g (97%) title compound, is buff white solid.ESI-MS (m/e): 639 [M+H]+。
5-3) prepare HClPro-Ala-Lys (Z)-OBzl
0.638g (1mmol) Boc-Pro-Ala-Lys (Z)-OBzl is dissolved in 10mL ethyl acetate.To obtaining under ice bath
In solution plus 15mL concentration is hydrogen chloride-ethyl acetate solution of 4N, and TLC (methylene chloride: methanol=1: 1) shows Boc-Pro-
Ala-Lys (Z)-OBzl disappears.Reaction mixture is concentrated under reduced pressure at room temperature, and with ethyl acetate dissolution, simultaneously room temperature subtracts residue again
Pressure concentration, 3 times repeatedly, cleared free hydrogen chloride.Residue anhydrous ether crystallization obtains 0.516g (90%) title compound
Object is directly used in the next step.ESI-MS (m/e): 539 [M+H]+。
Embodiment 6 prepares HClArg (NO2)-Pro-Ala-Lys(Z)-OBzl
Using the method for embodiment 3 from 798mg (2.5mmol) Boc-Arg (NO2) and 1.322g (2.3mmol) HCl
Pro-Ala-Lys (Z)-OBzl obtains 1.642g (78%) Boc-Arg (NO2)-Pro-Ala-Lys (Z)-OBzl, it is colorless solid.
ESI-MS(m/z)864[M+Na]+。
Using the method for embodiment 5-3 from 2.099g (2.5mmol) Boc-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl
1.9g (98%) title compound is obtained, is colorless solid.It is directly used in the next step.ESI-MS(m/z)742[M+H]+。
Embodiment 7 prepares Boc-Gly-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl
Using the method for embodiment 3 from 817mg (4.67mmol) Boc-Gly and 3.62g (4.77mmol) HClArg
(NO2)-Pro-Ala-Lys (Z)-OBzl obtains 3.43g (82%) title compound, it is colorless solid.ESI-MS(m/e)897[M+
H]+。
Embodiment 8 prepares HClGly-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl
Using the method for embodiment 5-3 from 2.241g (2.5mmol) Boc-Gly-Arg (NO2)-Pro-Ala-Lys(Z)-
OBzl obtains 2.02g (97%) title compound, is directly used in the next step.ESI-MS(m/e)797[M+H]+。
Embodiment 9 prepares 3,5-, bis--N-Boc-4,5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -6- acyl group-Lys
(Boc)-Gly-Arg(NO2)-Pro-Ala-Lys(Z)-OBzl(5)
Using the method for embodiment 3 from 819mg (1.38mmol) (6s) -3,5-, bis--Boc-4,5,6,7- tetrahydro -3H- miaows
Azoles [4,5-c] and pyridine -6- formyl-L-Lys (Boc) and 1.150g (1.38mmol) HClGly-Arg (NO2)-Pro-Ala-
Lys (Z)-OBzl obtains 680mg (36%) title compound, is colorless solid product.ESI-MS (m/e): 1374 [M+H]+；1H-
NMR (300MHz, DMSO-d6): δ/ppm=8.17-7.69 (m, 6H), 7.35-7.20 (m, 9H), 5.10 (s, 2H), 5.00 (s,
2H), 4.81 (m, 1H), 4.51-4.21 (m, 5H), 3.72-3.54 (m, 3H), 3.42-3.35 (m, 2H), 3.13 (s, 2H),
2.98-2.92 (m, 3H), 2.85-2.83 (m, 3H), 1.83-1.78 (m, 2H), 1.73-1.62 (m, 3H), 1.57 (s, 9H),
1.44 (s, 9H), 1.37 (s, 9H), 1.18-1.15 (m, 3H), 1.12-1.07 (m, 3H).
Embodiment 10 prepares 4,5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyridine -6- acyl group-Lys-Gly-Arg-Pro-
Ala- Lys(6)
To bis--N-Boc-4 of 50mg (0.036mmol) 3,5-, 5,6,7- tetrahydro -3H- imidazoles [4,5-c] and pyrrole under ice bath
Pyridine -6- acyl group-Lys (Boc)-Gly-Arg (NO2) in-Pro-Ala-Lys (Z)-OBzl plus 3mL TFA and 1mL TFMSA, stir
Mix TLC (CH after 30min2Cl2: MeOH=1: 1) shows raw material point disappear, stop reaction.Reactant is washed repeatedly with anhydrous ether
It washs, is concentrated to dryness, residue is dissolved with water, with ammonium hydroxide tune pH value to 8.Obtained solution is first removed with Sephadex G10
Salt, then with preparing columnT3 Prep OBDTM5 μm of 30 × 150mm purifying.5mg is lyophilized to obtain in corresponding fraction
(20%) title compound is colorless solid.ESI-MS (m/e): 805 [M+H]+；1H-NMR (500MHz, DMSO-d6): δ/ppm
=8.739 (s, 1H), 8.700 (m, 1H), 8.256 (m, 1H), 8.145 (m, 1H), 8.008 (m, 1H), 8.966 (m, 1H),
7.742 (m, 3H), 7.685 (m, 2H), 7.615 (m, 1H), 4.499-4.459 (m, 2H), 4.355-4.332 (m, 2H), 4.305
(m, 1H), 4.284-4.226 (m, 2H), 4.141 (m, 1H), 3.784-3.691 (m, 2H), 3.634 (m, 1H), 3.528 (m,
1H), 3.346 (m, 1H), 3.088-3.061 (m, 2H), 2.837 (m, 1H), 2.745-2.735 (m, 5H), 1.999 (m, 1H),
1.863-1.810 (m, 3H), 1.709-1.667 (m, 3H), 1.583-1.498 (m, 9H), 1.360-1.316 (m, 4H),
(1.202-1.188 m, 3H).
Experimental example 1 evaluates therapeutic effect of the compound 6 to ishemic stroke rat
SD male rat (280-300g) 10% chloraldurate (400mg/kg) intraperitoneal injection of anesthesia hits exactly from neck and omits
Portion to the right opens about 2cm long notch vertically, separates out in right common carotid artery, external carotid artery and neck and moves along fate on the inside of nutator
Arteries and veins.It is pressed from both sides respectively with noninvasive artery clamp and closes internal carotid opening and arteria carotis communis proximal part, cut an osculum in external carotid artery, ligatured
External carotid artery distal end unclamps the artery clamp of arteria carotis communis proximal part, takes 10 μ L blood, and blood is taken to be closed again with noninvasive artery clamp folder later
Arteria carotis communis proximal part.10 μ L blood of acquirement are fitted into 1mLEP pipe, first placing 30 minutes at normal temperature makes blood clotting, so
After be transferred in -20 DEG C of refrigerators and place 1 hour, keep blood clotting solid.Blood clotting is taken out after 1 hour, and 1mL physiology salt is added
Blood clotting is pounded size than more uniform tiny thrombus with steel shovel by water, and tiny thrombus suspension is then transferred to 1mL note
It is spare in emitter.While unclamping rat ICA folder, by the thrombus suspension in above-mentioned 1mL syringe slowly from rat neck
Outer artery passes through the brain of internal carotid injection rat to proximal part, then ligatures external carotid artery proximal part, opens internal carotid
With obtain artery clamp at arteria carotis communis, restore blood flow.Then the total vein of rat neck is separated, therapeutic agent is injected, ligatures vein, wound
3 drops penicillin (40mg/10mL) are added dropwise in place, sew up a wound, and wait animal revival.The dosage of test compound is 1nmol/kg
(being dissolved in physiological saline).Rat revive 24 hours after by Zealonga method (Wen Wang, Jingdong Xu, Lei Li,
Peichang Wang, Xunming Ji, Houxi Ai, Li Zhang, Lin Li, Neuroprotective effect of
Morroniside on focal cerebral ischemia in rats.Brain Research Bu lletin, 2010,
83,196-201) neurological functional deficit is evaluated.0 point indicates that, without any neurological deficit sign, 1 point of expression does not damage side
Forelimb not tensible, 2 points indicate to walk to not damaging skidding, and 3 points indicate to turn-take into shape walking of knocking into the back, 4 points of expressions to not damaging side
For the disturbance of consciousness without autonomous, 5 points of expressions are dead.The above each group appraisal result is subjected to statistics comparison, and makees t inspection.
Rat revives after 24 hours Zealonga method evaluation neurological functional deficits, breaks rapidly after being anaesthetized with urethane
Head takes brain, after brain tissue is placed in -20 DEG C of refrigerators 2 hours, from the coronal serial section of preceding antinion starting row about 2mm, and totally 6, so
It is placed in 2%TTC solution and is protected from light incubation 30min for 37 DEG C, and observe the color change of brain section, normal tissue is dyed by TTC
Red, and ischemic tissue is white.Then digital photo camera is used, is handled through SPSS statistical software, calculates and obstructs in coronal section
The area of dead volume and normal tissue, counts the Infarction volume percent value of each group, and does t inspection.
24 hours after rat revival, neurological functional deficit is evaluated by Zealonga method, appraisal result is included in table 1,
Rat cerebral infarction percent by volume is included in table 2.The result shows that 1nmol/kg compound 6 can be effectively protected the brain mind of rats with stroke
Through.Because the dosage of compound 6 is 1nmol/kg unlike the compound having disclosed needs 5 μm of ol/kg dosage.So,
1 time dosage reduces 5000 times.Obtain unexpected technical effect.
The treatment rat revival of 1 1nmol/kg compound 6 of table is scored afterwards for 24 hours
N=10；And physiological saline ratio p < 0.01 a).
2 1nmol/kg compound 6 of table treats rat brain Infarction volume percentage
N=10；And physiological saline group ratio p < 0.01, the p > 0.05 compared with t-PA a).
Claims (3)
1. the 4 of following formula, 5,6,7- tetrahydro -3H- imidazopyridine -6- formyl-Lys-Gly-Arg-Pro-Ala-Lys,
2. the 4,5,6,7- tetrahydro -3H- imidazopyridine -6- formyl-Lys-Gly-Arg-Pro-Ala-Lys's of claim 1
Preparation method, this method comprises:
(1) in the presence of dilute sulfuric acid, formaldehyde reacts at 60 DEG C with L-Histidine, generates 6s-4,5,6,7- tetrahydro -3H- imidazoles
And pyridine -6- carboxylic acid；
(2) in DCC and HOBt, there are bis--Boc-4,5,6,7- tetrahydro -3H- imidazopyridine -6- carboxylic acids of 6s-3,5- anhydrous four
Being condensed in hydrogen furans with Lys (Boc)-OBzl is bis--Boc-4,5,6,7- tetrahydro -3H- imidazopyridine -6- formyl of 6s-3,5- -
Lys(Boc)-OBzl；
(3) bis--Boc-4,5,6,7- tetrahydro -3H- imidazopyridine -6- formyl-Lys (Boc) of 6s-3,5--in the presence of Pd/C
OBzl sloughs OBzl in methanol solution and generates bis--Boc-4,5,6,7- tetrahydro -3H- imidazopyridine -6- formyl of 6s-3,5- -
Lys(Boc)；
(4) in the presence of dicyclohexylcarbodiimide Boc-Pro in anhydrous THF with and n-hydroxysuccinimide condensation be
Boc-Pro-OSu, in NaHCO3In the presence of Boc-Pro-OSu reacted with Ala generate Boc-Pro-Ala；
(5) Boc-Pro-Ala is Boc-Pro-Ala- with Lys (Z)-OBzl condensation in anhydrous THF in the presence of DCC and HOBt
Lys(Z)-OBzl；
(6) Boc-Pro-Ala-Lys (Z)-OBzl sloughs Boc protecting group and generates Pro- in hydrogen chloride-ethyl acetate solution
Ala-Lys(Z)-OBzl；
(7) Boc-Arg (NO in the presence of DCC and HOBt2) be condensed in anhydrous THF with Pro-Ala-Lys (Z)-OBzl as Boc-
Arg(NO2)-Pro-Ala-Lys(Z)-OBzl；
(8) Boc-Arg (NO in hydrogen chloride-ethyl acetate solution2) to slough Boc protecting group raw by-Pro-Ala-Lys (Z)-OBzl
At Arg (NO2)-Pro-Ala-Lys(Z)-OBzl；
(9) in the presence of DCC and HOBt Boc-Gly in anhydrous THF with Arg (NO2)-Pro-Ala-Lys (Z)-OBzl condensation be
Boc-Gly-Arg(NO2)-Pro-Ala-Lys(Z)-OBzl；
(10) Boc-Gly-Arg (NO in hydrogen chloride-ethyl acetate solution2)-Pro-Ala-Lys (Z)-OBzl slough Boc protection
Base generates Gly-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl；
(11) bis--Boc-4,5,6,7- tetrahydro -3H- imidazopyridine -6- formyl-Lys of 6s-3,5- in the presence of DCC and HOBt
(Boc) in anhydrous tetrahydro furan with Gly-Arg (NO2)-Pro-Ala-Lys (Z)-OBzl condensation be bis--Boc-4 of 6s-3,5-,
5,6,7- tetrahydro -3H- imidazopyridine -6- formyl-Lys (Boc)-Gly-Arg (NO2)-Pro-Ala-Lys(Z)-OBzl；
(12) compound prepared by step (11) is sloughed into protecting group, obtains 4,5,6,7- tetrahydro -3H- imidazopyridine -6-
Formyl-Lys-Gly-Arg-Pro-Ala-Lys.
3. the 4,5,6,7- tetrahydro -3H- imidazopyridine -6- formyl-Lys-Gly-Arg-Pro-Ala-Lys of claim 1 exists
Application in preparation treatment ishemic stroke drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510352820.1A CN106317195B (en) | 2015-06-23 | 2015-06-23 | Ring histidyl--KGRPAK, synthesis, thrombus related activity and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510352820.1A CN106317195B (en) | 2015-06-23 | 2015-06-23 | Ring histidyl--KGRPAK, synthesis, thrombus related activity and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106317195A CN106317195A (en) | 2017-01-11 |
| CN106317195B true CN106317195B (en) | 2019-09-17 |
Family
ID=57729446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510352820.1A Active CN106317195B (en) | 2015-06-23 | 2015-06-23 | Ring histidyl--KGRPAK, synthesis, thrombus related activity and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106317195B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101318994A (en) * | 2007-06-04 | 2008-12-10 | 北京大学 | Substituted tetrahydro-isoquinoline-3-carboxylic acid compound, preparation method and application thereof |
| CN102796167A (en) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | (S)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-formyl-L-prolyl-L-alanyl-L-amino acid, and preparation method and application thereof |
-
2015
- 2015-06-23 CN CN201510352820.1A patent/CN106317195B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101318994A (en) * | 2007-06-04 | 2008-12-10 | 北京大学 | Substituted tetrahydro-isoquinoline-3-carboxylic acid compound, preparation method and application thereof |
| CN102796167A (en) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | (S)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-formyl-L-prolyl-L-alanyl-L-amino acid, and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 寡肽药物先导结构的发现与优化;赵明等;《北京大学学报（医学版）》;20021231;第34卷(第5期);第507页第1.1节和第509页右栏最后1段 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106317195A (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106317186B (en) | Ring histidyl--KAK, synthesis, thrombus related activity and application | |
| CN103665107B (en) | Have thrombus dissolving simultaneously, remove free radical and the compounds of thrombus target function and its production and use | |
| US20230312644A1 (en) | Compounds having triple activities of thrombolysis, antithrombotic and radical scavenging | |
| CN103874414A (en) | Process and intermediates for preparing macrolactams | |
| CN102887941A (en) | PAK (polyester alkyd)/ imidazoline/RGD (arginine-glycine-aspartic acid) ternary conjugate and preparation method and use thereof | |
| CN102898505A (en) | ARPAK/imidazolidine/RGD ternary conjugate, preparation method and uses thereof | |
| CN102898507B (en) | Thrombolysis oligopeptide-imidazolidine binary conjugate, preparation method and uses thereof | |
| CN102875644A (en) | GRPAK/tetrahydroglyoxaline/RGD ternary conjugate as well as preparation method and application thereof | |
| CN106317195B (en) | Ring histidyl--KGRPAK, synthesis, thrombus related activity and application | |
| JPH0585933A (en) | Pharmaceutical for treating cataract | |
| CN106317194B (en) | Ring histidyl--KARPAK, synthesis, thrombus related activity and application | |
| JP2005538963A (en) | Method for producing L-alanine-L-glutamine | |
| CN108948146B (en) | 1R-methyl-beta-tetrahydrocarboline acyl-K (ARPAK) -RGDV, and synthesis, activity and application thereof | |
| CN106317171B (en) | Ring histidyl--KK, synthesis, thrombus related activity and application | |
| CN108929372A (en) | 1R- methyl-beta-tetrahydro carboline acyl-K (GRPAK)-RGDV, synthesis, activity and application | |
| CN102898506A (en) | RPAK/imidazolidine/RGD ternary conjugate, preparation method and uses thereof | |
| CN108948155A (en) | 1R- methyl-beta-tetrahydro carboline acyl-K (QRPAK)-RGDV, synthesis, activity and application | |
| CN106317190A (en) | Cyclohistidyl-KRPAK, and synthesis, thrombus related activity and applications thereof | |
| CN106317196A (en) | Imidazole-pyridine-formyl-K(K)-AA1-AA2-AA3-AK, synthesis, activity and application thereof | |
| CN106279360A (en) | Ring histidyl--KPAK, its synthesis, thrombosis related activity and application | |
| CN107459557A (en) | Left-handed Vc -2- oxygen acetyl-GRPAK, it is synthesized, activity and application | |
| CN108948145A (en) | 1R- methyl-beta-tetrahydro carboline acyl-K (PAK)-RGDV, synthesis, activity and application | |
| CN109776466A (en) | Benzoic acid derivative and its preparation method and application | |
| CN107459556A (en) | Left-handed Vc -2- oxygen acetyl-PAKPAK, it is synthesized, activity and application | |
| CN106589057A (en) | N-(PAK)-2,3-dioxide-isoquinoline-7-formyl-RGDV/F, synthesis, activity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |